Buscar
Estás en modo de exploración. debe iniciar sesión para usar MEMORY

   Inicia sesión para empezar


Por supuesto:

pharmacology chemotherapy

» Iniciar este curso
(Practica preguntas similares gratis)
Pregunta:

Rituximab use

Autor: Suzuki



Respuesta:

Rituximab is a monoclonal antibody that binds to a surface protein in non Hodgkin’s lymphoma cells and induces complement-mediated lysis, direct cytotoxicity, and induction of apoptosis. It is currently used with conventional anticancer drugs (eg, cyclophosphamide plus vincristine plus prednisone) in low-grade lymphomas. Rituximab is associated with hypersensitivity reactions and myelosuppression Rituximab was the first monoclonal antibody to be approved for the treatment of cancer. It is a genetically engineered, chimeric monoclonal antibody directed against the CD20 antigen that is found on the surfaces of normal and malignant B lymphocytes. CD20 plays a role in the activation process for cell-cycle initiation and differentiation. The CD20 antigen is expressed on nearly all B-cell nonHodgkin lymphomas but not in other bone marrow cells. Rituximab has proven to be effective in the treatment of posttransplant lymphoma and in chronic lymphocytic leukemia.


0 / 5  (0 calificaciones)

1 answer(s) in total

Autor

Suzuki
Suzuki